These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21802490)

  • 21. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
    Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prostate cancer and apoptosis].
    Mayora A; Arvelo F
    Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
    Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
    BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
    Huss WJ; Gray DR; Greenberg NM; Mohler JL; Smith GJ
    Cancer Res; 2005 Aug; 65(15):6640-50. PubMed ID: 16061644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hunterian Lecture. Characterisation of human prostate epithelial progenitor differentiation in response to androgens.
    Heer R
    Ann R Coll Surg Engl; 2011 Sep; 93(6):424-8. PubMed ID: 21929909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
    Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
    Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The molecular and cellular origin of human prostate cancer.
    Packer JR; Maitland NJ
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1238-60. PubMed ID: 26921821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel endocrine aspects of prostate cancer.
    Visakorpi T
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):1-2. PubMed ID: 22465021
    [No Abstract]   [Full Text] [Related]  

  • 29. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer.
    Blok LJ; Chang GT; Steenbeek-Slotboom M; van Weerden WM; Swarts HG; De Pont JJ; van Steenbrugge GJ; Brinkmann AO
    Br J Cancer; 1999 Sep; 81(1):28-36. PubMed ID: 10487609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer stem cells: the role of androgen and estrogen receptors.
    Di Zazzo E; Galasso G; Giovannelli P; Di Donato M; Di Santi A; Cernera G; Rossi V; Abbondanza C; Moncharmont B; Sinisi AA; Castoria G; Migliaccio A
    Oncotarget; 2016 Jan; 7(1):193-208. PubMed ID: 26506594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
    Gao J; Arnold JT; Isaacs JT
    Cancer Res; 2001 Jul; 61(13):5038-44. PubMed ID: 11431338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel class of pyranocoumarin anti-androgen receptor signaling compounds.
    Guo J; Jiang C; Wang Z; Lee HJ; Hu H; Malewicz B; Lee HJ; Lee JH; Baek NI; Jeong JH; Kim DK; Kang KS; Kim SH; Lu J
    Mol Cancer Ther; 2007 Mar; 6(3):907-17. PubMed ID: 17363485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens.
    Granchi S; Brocchi S; Bonaccorsi L; Baldi E; Vinci MC; Forti G; Serio M; Maggi M
    Prostate; 2001 Dec; 49(4):267-77. PubMed ID: 11746273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen action during prostate carcinogenesis.
    Wang D; Tindall DJ
    Methods Mol Biol; 2011; 776():25-44. PubMed ID: 21796518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors.
    Rouet V; Bogorad RL; Kayser C; Kessal K; Genestie C; Bardier A; Grattan DR; Kelder B; Kopchick JJ; Kelly PA; Goffin V
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15199-204. PubMed ID: 20699217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular regulation of androgen action in prostate cancer.
    Dehm SM; Tindall DJ
    J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationship between HER-2/neu over-expression and androgen independent prostate cancer].
    Bai Q; Chen F; Qi J; Chen JH; Wang YX
    Zhonghua Nan Ke Xue; 2007 May; 13(5):414-6. PubMed ID: 17569256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
    Krueckl SL; Sikes RA; Edlund NM; Bell RH; Hurtado-Coll A; Fazli L; Gleave ME; Cox ME
    Cancer Res; 2004 Dec; 64(23):8620-9. PubMed ID: 15574769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
    Kim IY; Seong DH; Kim BC; Lee DK; Remaley AT; Leach F; Morton RA; Kim SJ
    Cancer Res; 2002 Jul; 62(13):3649-53. PubMed ID: 12097269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.